Clinical Trials Logo

Clinical Trial Summary

To investigate and compare the possible response of Panadol® and SafeTynadol® formulations in healthy volunteers.


Clinical Trial Description

Acetaminophen (AAP) is the most popular used analgesic/ antipyretic drug with serious hepatotoxic adverse effects; suicidal or unintentional overdose of AAP-induced hepatotoxicity. Cytochrome P450 2E1 (CYP2E1) is thought contribute to the responsible reactive metabolite N-acetyl-p-benzoquinone (NAPQI) of AAP overdose-induced hepatotoxicity. Pharmaceutical excipients are inactive ingredients that are added to a pharmaceutical compound. The objective of this study was to investigate the possible response of Panadol® (AAP alone) and SafeTynadol® (AAP with various selected excipients combination) formulations, while observing the AAP toxic metabolites (AAP-Cys) circumstances change in healthy volunteers. According to the current safety data, could be potentially develop hepatotoxicity-free AAP new formulation drug. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03451487
Study type Interventional
Source Sinew Pharma Inc.
Contact
Status Completed
Phase N/A
Start date May 19, 2022
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02322879 - Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing Phase 4
Completed NCT01465542 - Treatment of APAP Toxicity With IV and Oral NAC 2008-2011
Completed NCT01575847 - Adduct Dipstick for Diagnosis of Acetaminophen Toxicity N/A
Enrolling by invitation NCT01005173 - Acetaminophen Biomarkers N/A
Completed NCT00725179 - Treatment of Acetaminophen Toxicity With N-acetylcysteine N/A